Section 29: how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Section 29 is
Origin and authorising body. United Kingdom and several Commonwealth jurisdictions referencing Section 29 of national pharmacy or medicines legislation. The authorising body for each individual case is the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK; equivalent national pharmacy regulators in other Commonwealth jurisdictions, acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Section 29 references in UK pharmacy law historically appeared in the Medicines Act 1968 (now superseded by the Human Medicines Regulations 2012). Several Commonwealth pharmacy statutes retain Section 29 numbering for special-access provisions covering individual-patient supply of unregistered medicines. New Zealand's Medicines Act 1981 retains a Section 29 provision permitting medical practitioners to procure unapproved medicines for a specific patient.
Section 29 (in jurisdictions retaining the term) is the historical or current statutory citation for individual-patient supply of unregistered medicines under pharmacy law. The operational substance is similar to the Named-Patient or specials framework: the treating physician issues a prescription, the dispensing pharmacy obtains the medicine from a licensed supplier, and the regulator authorises the supply chain rather than each individual case.
In the UK, the current operative framework is Regulation 167 of the Human Medicines Regulations 2012 (Individual Patient Supply), which superseded the older Section 29 references. In New Zealand, Section 29 remains operative under the Medicines Act 1981 and is the principal route for medical practitioners to procure unapproved medicines. Some Commonwealth jurisdictions retain Section 29 terminology in their national pharmacy acts. The cross-border operational pattern is consistent across these jurisdictions: prescriber leads, dispensing pharmacy supplies, regulator audits.
This page consolidates Reserve Meds's operational view of the Section 29 (UK Medicines Act) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Section 29 (UK Medicines Act)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Section 29
Section 29 supply is used by prescribers in the relevant jurisdiction on behalf of named patients. The framework is jurisdiction-specific and does not directly govern cross-border supply; cross-border patients use parallel home-country named-patient frameworks.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Section 29
Unregistered medicines for individual-patient supply across the same range as Named-Patient Programs: oncology, rare disease, dermatology, paediatrics, post-approval indications.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Section 29 (UK Medicines Act) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Section 29 (UK Medicines Act) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Section 29 (UK Medicines Act) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Section 29 (UK Medicines Act) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Section 29 (UK Medicines Act) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Section 29 (UK Medicines Act) authorisation as the legal basis for import but does recognise a Section 29 (UK Medicines Act) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Section 29 application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Prescriber's prescription with clinical justification.
- Patient identifier and clinical history.
- Dispensing pharmacy's supply documentation.
- Manufacturer or wholesaler chain-of-custody.
- Informed consent for unregistered-medicine use.
Typical timeline
Routine cases: 1 to 4 weeks. Imported cases: 3 to 8 weeks depending on source-country and destination-country requirements.
Costs and reimbursement
Jurisdiction-specific reimbursement applies. Cross-border patients pay the relevant per-country acquisition cost.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Section 29 (UK Medicines Act) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Section 29 (UK Medicines Act) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.